(NASDAQ: KURA) Kura Oncology's forecast annual revenue growth rate of 85.44% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 65.42%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10.4%.
Kura Oncology's revenue in 2025 is $53,883,000.On average, 5 Wall Street analysts forecast KURA's revenue for 2025 to be $15,639,005,747, with the lowest KURA revenue forecast at $1,453,589,298, and the highest KURA revenue forecast at $29,564,391,222. On average, 6 Wall Street analysts forecast KURA's revenue for 2026 to be $17,182,071,542, with the lowest KURA revenue forecast at $2,559,932,264, and the highest KURA revenue forecast at $36,436,638,403.
In 2027, KURA is forecast to generate $30,350,944,542 in revenue, with the lowest revenue forecast at $4,554,579,800 and the highest revenue forecast at $94,378,322,921.